Lipella Pharmaceuticals, Inc. · OTC:LIPO

Lipella Pharmaceuticals — Investor Presentation (January 2024)

25 slides from Lipella Pharmaceuticals's investor presentation, January 2024

  1. Slide 1: A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need

    A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com

  2. Slide 2: Disclaimers

    NASDAQ:LIPO Disclaimers The info rmatio n in this pre s entatio n is be ing pro vid e d s o yo u c an familiarize yo urs e lf with Lipella P harmac e utic als Inc . (“Lipe lla,” the “C o mpany,” “we ,” “us ,” o r “o ur”) d uring this info rmatio nal me e ting. W e re q ue s t that yo u ke e p any in

  3. Slide 3: Mission

    NASDAQ:LIPO Mission Lip e lla is c o mmitte d to p ro vid ing s up p o rtive c are to c anc e r s urvivo rs . O ur mis s io n is to d e ve lo p and c o mme rc ialize tre atme nts fo r s e rio us d is e as e s re s ulting fro m c anc e r tre atme nts inc lud ing rad iatio n and c he mo the rap y. A C

  4. Slide 4: Business Growth Strategy

    NASDAQ:LIPO Business Why rare and orphan drugs? Growth • Lipella can be first to market by pursuing conditions for which there are no current FDA approved treatments. • Requires smaller and less costly drug trials with greater flexibility from the Strategy FDA. • Orphan drug market exclusivity limit

  5. Slide 5: About / Market Data

    NASDAQ:LIPO Market Data About SYMBOL NASDAQ: LIPO Lipe lla P harmac e utic als is a c linic al- s tag e bio te c hno lo g y Price as of 1-05-2024 $1.09 c o mpany d e ve lo ping ne w d rug s 52 Week Range $0.85 - $6.10 by re f o rmulating ac tive ag e nts in e xis ting g e ne ric d rug s f o r Averag

  6. Slide 6: Overview of Opportunity

    NASDAQ:LIPO Overview of Opportunity Drug Development Drug Delivery Lead product candidate, LP - 10, a 505(b)(2) drug Proprietary drug delivery technology with candidate for hemorrhagic cystitis. potential applications in bladder, urethra, oral cavity, esophageal and colonic. LP- 10 granted FDA Orpha

  7. Slide 7: Executive Summary

    NASDAQ:LIPO Executive Summary Emerging, clinical - stage, proprietary 505(b)(2) opportunity Drug - Delivery Focused Biotech Impressive Revenue Potential O p timize d f o r 5 0 5 (b )(2) e p ithe lial tis s ue s $20,000 $1.2 billion annual revenue annual revenue P ate nte d lip o s o mal lo c al d ru

  8. Slide 8: Cancer Survivorship and Potential Addressable Market

    NASDAQ:LIPO Cancer Prostate Cancer Uterine Corpus Cancers Rectal & Other Pelvic Survivorship 700,000 1 200,000 1 300,000 1 and Potential P e lvic R ad iatio n S urvivo rs P e lvic R ad iatio n S urvivo rs P e lvic R ad iatio n S urvivo rs 42,000 2 12,000 2 18,000 2 Addressable Severe HC Survivors Se

  9. Slide 9: Asset Pipeline

    NASDAQ:LIPO Asset Pipeline A growing pipeline with strong patent protection Product Target Marketing Next Anticipated Preclinical Phase 1 Phase 2 Phase 3 Candidate Indication Approval Milestone FDA Type - C He mo rrhag ic LP- 10 mtg C o mple te d C ys titis No v. 7, 20 23 P has e - 2a IND O ral Lic

  10. Slide 10: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss

    NASDAQ:LIPO Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is a serious, life - threatening bladder damage from pelvic radiation therapy and/or bladder - toxic chemotherapy. Millio ns o f patie nts are 20 % o f the s e patie nts An inc re as ing US Ye ars afte r re c e iv

  11. Slide 11: LP-10 for Hemorrhagic Cystitis

    NASDAQ:LIPO LP- 10 for Hemorrhagic Cystitis Liposomal tacrolimus treatment for hemorrhagic cystitis Potent vasoconstrictor; re d uc e s c apillary blo o d f lo w to the blad d e r lume n Sterile powder Potent anti - inflammatory; inhibits c yto kine Easy to deliver c as c ad e and re d uc e s injury

  12. Slide 12: LP-10: an Outstanding Drug Candidate

    NASDAQ:LIPO LP- 10: an Outstanding Drug Candidate Multiple reasons increase LP - 10 probability of success • W e ll K no wn me c hanis m o f Well known Potential ac tio n mechanism 505(b)(2) $1.2 billion pathway Ongoing of action revenue • P re - c linic al e f f ic ac y clinical evidence • 5 0 5 (b

  13. Slide 13: LP-10: Phase 2a Trial

    NASDAQ:LIPO LP- 10: Phase 2a Trial A Phase 2a clinical trial (NCT01393223): Top line results Next Steps • All subjects tolerated LP - 10 • Type - C meeting with the FDA • Multi - center, dose - escalation instillations with no serious adverse completed Nov. 7, 2023 study events (SAE) reported • FDA

  14. Slide 14: Bleeding: Cystoscopy & Microscopy

    NASDAQ:LIPO Bleeding: Cystoscopy & Microscopy A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 14

  15. Slide 15: LP-10 Phase 2b Trial Design

    NASDAQ:LIPO LP- 10 Phase 2b Trial Design Key criteria: R and o mize d , d o uble - blind , plac e bo c o ntro lle d , multi- c e nte r c linic al trial o f 36 Male and Fe male he mo rrhagic c ys titis patie nts , rand o mize d 1:1:1 S ubje c ts will be rand o mize d into o ne o f thre e gro ups : 2m

  16. Slide 16: LP-310 for Oral Lichen Planus

    NASDAQ:LIPO LP- 310 for Oral Lichen Planus Oral Lichen Planus (OLP) is a chronic inflammatory, T- cell - mediated autoimmune oral mucosal disease • P ainful and c o me s with the ris k o f c o mp lic atio ns inc lud ing infe c tio ns , s c arring , s tre s s and d e p re s s io n. • Has malig nant p

  17. Slide 17: Manufacturing Capabilities

    NASDAQ:LIPO Manufacturing Capabilities • Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products. • LP- 10 has been produced at high quantities in this facility for Lipella's clinical trials. • The facility is also used for d

  18. Slide 18: Experienced Management Team

    NASDAQ:LIPO Experienced Management Team Lipella is led by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Chief Executive Officer Chief Medical Officer • 23 + Ye ars E xpe rie nc e • 3 0 + Ye ars E xpe rie nc e •

  19. Slide 19: Key Takeaways

    NASDAQ:LIPO Key Takeaways Drug Development Drug Delivery Lead product candidate, LP - 10, a 505(b)(2) drug candidate for Proprietary drug delivery technology with hemorrhagic cystitis. potential applications in bladder, urethra, LP- 10 granted FDA Orphan Drug Designation; potential candidate oral ca

  20. Slide 20: A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need

    A Clinical Stage Biotechnology Company Addressing Serious Diseases with NASDAQ:LIPO Significant Unmet Need Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412- 894 - 1853 lipellapharmaceuticals.com

  21. Slide 21: LP-10 Phase 2a Trial Patient Demographics

    NASDAQ:LIPO LP- 10 Phase 2a Age, years Mean 67 Comment Range 25- 89 Trial Patient Race • White 9 Demographics • Non - White 4 Radiation induced HC 11 Chemotherapy induced HC 2 Cancer • Prostate cancer 9 • Bladder cancer 2 • Lymphoma 2 Duration of HC years 4 Range 1- 14 years medication, HBO, cathete

  22. Slide 22: LP-10 Safety

    NASDAQ:LIPO Number Comment LP- 10 Safety Product related significant adverse events 0 Subject discontinuations 0 Number of subjects with adverse events 6/13 12 AEs reported in 6 subjects Adverse events (AE) 2 mg : 4 AEsin 3 subjects 4 mg: 2 AEs in 1 subject 8 mg: 6 AEs in 2 subjects Bladder spasm, u

  23. Slide 23: Hematuria & Incontinence

    NASDAQ:LIPO Hematuria & Incontinence A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 23

  24. Slide 24: Dose Response: Bleeding by Cystoscopy

    NASDAQ:LIPO Dose Response: Bleeding by Cystoscopy A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 24

  25. Slide 25: Dose Response: Urinary Urge Incontinence

    NASDAQ:LIPO Dose Response: Urinary Urge Incontinence A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 25

Lipella Pharmaceuticals — Investor Presentation (January 2024) on 6ix